How to win in the evolving early-stage NSCLC landscape
Strategic considerations to successfully adapt to the rapidly changing NSCLC global market following the introduction of checkpoint inhibitors in resectable disease (non-driver)
Understanding the needs of endometriosis patients through social media data
Social media spaces have transitioned into vital outlets for Endometriosis patients to openly discuss their experiences. Read our report.
Technology solutions for privacy challenges
Privacy challenges have existed for some years now and intensified in the last decade. So, what is a solution to these challenges? Since the legislative environment is becoming more conservative, innovative technology could be the answer. Learn more.
Immunotherapies are the scientific answer to cancer, but how important is marketing?
This white paper considers the key issues in oncology of: the rise of immuno-oncology brands, what is happening in the mind of the Oncologists, changing paradigm within Oncology and what does this mean for pharma?
Evolving regulatory and reimbursement landscape
Cancer is a healthcare priority in all APAC markets. We provide an overview of China, Hong Kong, Japan, Singapore, South Korea and Taiwan.
The key to successful German HTA submissions
Registry studies and the extended application-accompanying data collection EAD in the context of the AMNOG process.
Optimal evidence strategy for price and reimbursement
How patient preference studies can add value to your dossier in Europe. How to derive potential evidence from preferences that allow optimized evidence.
Promises and pitfalls of D2C genetic testing
Today, DTC genetic testing relies heavily on informed consumers, which Is a challenge due to the rapidly developing genetic science that underpins it.
Improving diagnostic accuracy in rare disease
Our behavioural approach allowed us to identify a game-changing insight which would not have been achieved through traditional interviewing alone.